Blog

Jul 2018

DIA 2018 Global Annual Meeting: was this year’s theme the most dead-on yet?

By | 2018-07-17T09:10:07+01:00 July 16, 2018|Blog|Comments Off on DIA 2018 Global Annual Meeting: was this year’s theme the most dead-on yet?

The dramatic expansion of prescription drug deaths inspired this year's theme "driving insights to action". Insights that could be deployed through novel disruptive technologies such as Risk-based Quality Management (RBQM). Cyntegrity's Johann Proeve and Nimita Limaye were in Boston and share their observations with us.

Jun 2018

Medical Devices: Managing Risks Beyond Bullet Proof Clinical Evidence

By | 2018-06-12T14:41:15+01:00 June 6, 2018|Blog, Weekly RBM Feature|Comments Off on Medical Devices: Managing Risks Beyond Bullet Proof Clinical Evidence

The EU MDR is setting the stage for busy times ahead. The continuous need for clinical evidence, the increasing complexity of new medical devices, and the size and global nature of medical device trials introduce a greater potential for error. Learn how a risk-based approach enables MedTech manufacturers to better understand, manage and mitigate the growing uncertainties.

May 2018

Key Risk Indicators Reveal Blind Spots in Clinical Trials

By | 2018-05-16T09:02:30+01:00 May 15, 2018|Blog|Comments Off on Key Risk Indicators Reveal Blind Spots in Clinical Trials

By design, the traditional spot-checking type of audits leave a blind spot on systemic quality threats. Key Risk Indicators however, form the core of a widely applicable concept that captures all relevant risks in scope and provides project managers and QM experts targeted and objective updates on actionable issues and trends.

May 2018

Interview: “Oncology Trials are Different”

By | 2018-05-03T13:23:27+01:00 May 3, 2018|Blog, News|Comments Off on Interview: “Oncology Trials are Different”

Many risks in clinical trials seem therapy specific. To illustrate this, Dr Johann Proeve shares real life use cases he experienced during his years as Head of Global Data Management at Bayer HealthCare.

May 2018

“OncoRACT” – The First Therapy Specific RACT for Clinical Trials

By | 2018-05-03T13:07:48+01:00 May 1, 2018|Blog, News|Comments Off on “OncoRACT” – The First Therapy Specific RACT for Clinical Trials

Many risks in clinical trials are therapy specific. Because of that, the currently available tools addressing those risks are now becoming therapy specific as well. The first therapy focused risk library Oncology RACT (OncoRACT) recently got available.

Mar 2018

Adaptive Monitoring: Anticipating The Human Factor

By | 2018-03-21T19:31:12+00:00 March 21, 2018|Blog, Case Study|Comments Off on Adaptive Monitoring: Anticipating The Human Factor

An effective way to control risks during a clinical trial is to anticipate events induced by human factor before the study even begins. Dr Johann Proeve's third chapter on Adaptive Monitoring talks about how human factor is complementary to numeric data.

Mar 2018

The Three Biggest Challenges in RBM Related to Key Risk Indicators

By | 2018-03-14T17:33:53+00:00 March 14, 2018|Blog|Comments Off on The Three Biggest Challenges in RBM Related to Key Risk Indicators

Our online KRI (Key Risk Indicator) survey indicated that finding the right calculation method seems the most challenging aspect of the application of KRIs. In addition our survey showed that the vast majority (> 95%) makes use of KRIs. Do these results surprise you?

Mar 2018

Adaptive Monitoring: Beyond Data Trends and Timely Performance

By | 2018-06-03T14:21:15+01:00 March 7, 2018|Blog, Case Study|Comments Off on Adaptive Monitoring: Beyond Data Trends and Timely Performance

Adaptive Monitoring is not a “status quo”, it is a dynamic response to clinical research that drives monitoring scope and activities to the evolving areas of greatest need which have the most potential to positively impact. Each clinical study requires its own tailored monitoring approach ensuring risks are minimized.

Feb 2018

What is the Cost of Poor Quality in Pharma?

By | 2018-04-05T15:16:39+01:00 February 20, 2018|Blog, Library|Comments Off on What is the Cost of Poor Quality in Pharma?

Quality is a business decision. Everyone instinctively knows that poor quality doesn't come cheap, however until now no attempt was made to calculate the real difference between good and poor quality in clinical trials. Most of the issues that impact cost and expenses are lurking just below the tip of the iceberg.

Upcoming Events

  1. SCDM 2018 ANNUAL CONFERENCE – Seattle

    September 23 - September 26
  2. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access